incretin mimetics glp 1 agonists GLP-1s & Beyond: Understanding Mimetic Opportunities PDB-101: Diabetes Mellitus: Diabetes Mellitus:
Description
But Mounjaro (tirzepatide) consistently shows the strongest results
It is a predictable pharmacological consequence of activating a receptor that was always going to do this
REWIND (2019) Dulaglutide extended benefit into a broader, lower-risk population challenging the idea this was only for those with established disease
This remains to be investigated
69705-5/asset/079012c9-a24f-4391-ba39-2f5d03668f6f/main.assets/gr1_lrg.jpg)
doi: 10.1056/NEJMoa066254, PMID: [DOI] [PubMed] [Google Scholar] 10
